EligibleTrials

Tralokinumab: clinical trials recruiting now

3
Recruiting trials
4
Conditions studied
1
US states with sites
2
Countries

FDA drug label

FDA-approved
Yes. Tralokinumab appears in the FDA drug-label database. Marketed as Adbry.
Drug class
Interleukin-13 Antagonist (FDA established pharmacologic class)
Mechanism of action
Interleukin-13 Antagonists (as stated on the FDA label)

FDA-approved use

ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ADBRY is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ( 1 )

FDA recalls / enforcement

Reason (FDA)ClassificationStatusInitiated
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber. — LEO PHARMA INC Class II (FDA: may cause temporary or reversible harm) Ongoing 2026-02-10

FDA label via openFDA

Phase breakdown

Not applicable 3

Conditions being studied

ConditionTrials
Eczema · Tralokinumab for Eczema3
Atopic Dermatitis2
Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region1
Psoriasis1

Recruiting trials involving Tralokinumab

Common questions

Is Tralokinumab FDA-approved?

Yes, marketed as Adbry.

How many recruiting trials involve Tralokinumab?

3 recruiting trials across 4 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.